Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney Disease
Halle (Saale) / Munich, Germany, July 18, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and […]
Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease
Halle (Saale) / Munich, Germany, July 9, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and […]
Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting
Halle (Saale) / Munich, Germany, June 21, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon, or the Company), a clinical stage company focused on […]
Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease
• Additional kidney function analyses strongly support Vivoryon’s shift in strategic focus to inflammatory and fibrotic diseases, and are a further step towards securing Company’s future […]
Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024
Halle (Saale) / Munich, Germany, May 15, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and […]
Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meetingon June 21, 2024
Halle (Saale) / Munich, Germany, May 08, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and […]
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates
Halle (Saale) / Munich, Germany, April 24, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and […]
Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024
Halle (Saale) / Munich, Germany, April 16, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and […]
Vivoryon Therapeutics N.V. Announces Changes to Board Composition
Halle (Saale) / Munich, Germany, March 15, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and […]
Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease
Halle (Saale) / Munich, Germany, March 4, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and […]
Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024
Halle (Saale) / Munich, Germany, January 8, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and […]
Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
Halle (Saale) / Munich, Germany, December 6, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and […]
Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023
Halle (Saale) / Munich, Germany, November 28, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and […]
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference
Halle (Saale) / Munich, Germany, November 7, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and […]
Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program FollowingR&D Event and VIVA-MIND DSMB Dose Decision
Halle (Saale) / Munich, Germany, October 26, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and […]
Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed at Highest Investigated Dose
Halle (Saale) / Munich, Germany, October 23, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and […]
Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion Leaders
Halle (Saale) / Munich, Germany, October 17, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and […]
Vivoryon Therapeutics N.V. Announces Virtual R&D Event with Key Opinion Leaders and Upcoming Conference Participation
Halle (Saale) / Munich, Germany, October 5, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and […]
Vivoryon Therapeutics N.V. Extraordinary General Meeting Approved Appointment of New Executive Directors to the Board
Halle (Saale) / Munich, Germany, September 15, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon, or the Company), a clinical stage company focused on […]
Vivoryon Therapeutics N.V. Reports H1 2023 Financial Results and Highlights Operational Progress
Both VIVIAD and VIVA-MIND studies on track; final data from VIVIAD expected in Q1/2024, and a study update on VIVA-MIND expected in Q4/2023 Varoglutamstat demonstrates very […]
Vivoryon Therapeutics N.V. to Report Half Year 2023 Financial Results and Operational Progress on September 07, 2023
Halle (Saale) / Munich, Germany, August 31, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and […]
Vivoryon Therapeutics N.V. Extraordinary General Meeting to Confirm New Executive Director Appointments to the Board, Being Held on September 15, 2023
Halle (Saale) / Munich, Germany, August 4, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon, or the Company), a clinical stage company focused on […]
Vivoryon Therapeutics N.V. Announces Proposed Appointment of Dr. Frank Weber as Chief Executive Officer
Halle (Saale) / Munich, Germany, August 4, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon, or the Company), a clinical stage company focused on […]
Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer’s Disease
Halle (Saale) / Munich, Germany, July 16, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and […]
Vivoryon Therapeutics N.V. Announces CEO Transition Plan
Halle (Saale) / Munich, Germany, June 15, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and […]
Vivoryon Therapeutics N.V. to Participate in Upcoming Conferences
Halle (Saale) / Munich, Germany, June 1, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and […]
Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 25 Million
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, SOUTH […]
Vivoryon Therapeutics Launches Capital Increase by Way of an Accelerated Bookbuild Offering
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, SOUTH […]
Vivoryon Therapeutics N.V. Reports Q1 2023 Financial Results and Highlights Operational Progress
Halle (Saale) / Munich, Germany, May 16, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and […]
Vivoryon Therapeutics N.V. to Hold its 2023 Annual General Meeting on June 21, 2023
Halle (Saale) / Munich, Germany, May 9, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and […]
Vivoryon Therapeutics N.V. to Report Q1 2023 Financial Results and Operational Progress on May 16, 2023
Halle (Saale) / Munich, Germany, May 9, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and […]
Vivoryon Therapeutics N.V. Announces Planned Changes to Board Composition at 2023 Annual General Meeting
Halle (Saale) / Munich, Germany, May 1, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and […]
Vivoryon Therapeutics N.V. to Participate in Upcoming Conferences
Halle (Saale) / Munich, Germany, April 24, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and […]
Vivoryon Therapeutics N.V. Reports Full Year 2022 Financial Results and Highlights Operational Progress
Halle (Saale) / Munich, Germany, April 19, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and […]
Vivoryon Therapeutics N.V. to Report Full Year 2022 Financial Results and Operational Progress on April 19, 2023
Halle (Saale) / Munich, Germany, April 14, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and […]
Vivoryon Therapeutics N.V. Provides Progress Update on Varoglutamstat Clinical Development for the Treatment of Alzheimer’s Disease
Halle (Saale) / Munich, Germany, March 28, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and […]
Vivoryon Therapeutics N.V. to Present at Upcoming Conferences
Halle (Saale) / Munich, Germany, February 21, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and […]
Vivoryon Therapeutics N.V. to Present at the 2023 BIO CEO & Investor Conference
Halle (Saale) / Munich, Germany, February 3, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and […]
Vivoryon Therapeutics to Present a Clinical Update on its Novel Oral Small Molecule Varoglutamstat at Clinical Trials on Alzheimer’s Disease Conference (CTAD)
· An update on dose selection and interim blinded safety results from varoglutamstat´s Phase 2b study (VIVIAD) will be presented Halle (Saale) / Munich, Germany, November 28, 2022 – Vivoryon Therapeutics […]
Vivoryon Therapeutics Announces Successful Listing of 2,054,796 Shares
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA. Listing of additional […]
Vivoryon Therapeutics N.V. Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
HALLE (SAALE) / MUNICH, GERMANY, November 22, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule […]
Vivoryon Therapeutics N.V. to Report Q3 2022 Financial Results and Operational Progress on November 22, 2022
HALLE (SAALE) / MUNICH, GERMANY, November 14, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small […]
Vivoryon Therapeutics N.V. Reports H1 2022 Financial Results and Highlights Operational Progress
HALLE (SAALE) / MUNICH, GERMANY, September 30, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule […]
Vivoryon Therapeutics Announces Successful Private Placement of up to EUR 30 Million
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA. Significant commitment from […]
Vivoryon Therapeutics N.V. to Report H1 2022 Financial Results and Operational Progress on September 30, 2022
HALLE (SAALE) / MUNICH, GERMANY, September 26, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small […]
Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique Opportunity in AD
Safety data from 181 patients show no on-target toxicity and no clinical signs of ARIA Therapeutic dose of 600 mg varoglutamstat given twice daily selected by […]
Vivoryon Therapeutics N.V. Presents Preclinical Evidence of Combination Therapy Potential for Varoglutamstat in AD at AAIC 2022
Data underscore the unique potential of Vivoryon’s N3pE-focused strategy in mono- and combination therapy settings in AD Combination treatment of aducanumab and varoglutamstat achieves additive effect […]
Vivoryon Therapeutics N.V. Reports Positive Independent Data Safety Monitoring Board Recommendation for Phase 2b Study of Varoglutamstat in AD
Parallel group, dose-finding part of the study completed DSMB recommends that the study should proceed with a maximum dose of 600 mg BID varoglutamstat or placebo […]
Vivoryon Therapeutics N.V. Reports Outcome of Annual General Meeting 2022
All proposed resolutions approved All existing members re-appointed Board strengthened and diversified HALLE (SAALE) / MUNICH, GERMANY, June 22, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: […]
Vivoryon Therapeutics N.V. Reports Q1 2022 Financial Results and Highlights Operational Progress
HALLE (SAALE) / MUNICH, GERMANY, June 15, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development […]
Vivoryon Therapeutics N.V. to Report First Quarter 2022 Financial Results on June 15, 2022
Halle (Saale) / Munich, Germany, June 08, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development […]
Vivoryon Therapeutics N.V. to Hold its Annual General Meeting on June 22, 2022
Halle (Saale) / Munich, Germany, May 11, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon; or the Company), a clinical stage company focused on discovery and development of […]
Vivoryon Therapeutics N.V. Reports Full Year 2021 Financial Results and Highlights Operational Progress
Substantial progress in clinical development of QPCT/L inhibitor varoglutamstat, EU and U.S. clinical studies in AD on track FDA Fast Track designation for lead product candidate […]
Vivoryon Therapeutics N.V. to Report Full Year 2021 Financial Results and Operational Progress on April 28, 2022
Halle (Saale) / Munich, Germany, April 21, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development […]
Vivoryon Therapeutics N.V. to Participate at Upcoming Investor Conferences
HALLE (SAALE) / MUNICH, GERMANY, April 20, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development […]
Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 21 Million
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA. Halle (Saale) / Munich, Germany, April […]
Vivoryon Therapeutics Launches Capital Increase by Way of Private Placement
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA. Halle (Saale) / Munich, Germany, March […]
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference
HALLE (SAALE) / MUNICH, GERMANY, March 7, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development […]
Vivoryon Therapeutics and Simcere Announce CDE Approval of Chinese Clinical Trial Application for Varoglutamstat (SIM0408, PQ912) in Patients with Alzheimer’s Disease
Halle (Saale) / Munich, Germany and Nanjing, China, February 28, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines and […]
Vivoryon Therapeutics N.V. to Participate in Upcoming Investor Conferences
HALLE (SAALE) / MUNICH, GERMANY, January 4, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development […]
Vivoryon Therapeutics Receives FDA Fast Track Designation for Varoglutamstat in Early Alzheimer’s Disease
Halle (Saale) / Munich, Germany December 22, 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development of […]
Vivoryon Therapeutics N.V. Reports Q3 2021 Financial Results and Highlights Operational Progress
HALLE (SAALE) / MUNICH, GERMANY, November 4, 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development […]
Vivoryon Therapeutics N.V. to Report Third Quarter 2021 Financial Results on November 4, 2021
Halle (Saale) / Munich, Germany, November 1, 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development of […]
Vivoryon Therapeutics Provides Update on Business and Progress of Varoglutamstat Clinical Development in Alzheimer’s Disease
This announcement contains Inside Information as defined under the Market Abuse Regulation (EU) No. 596/2014 Halle (Saale) / Munich, Germany October 18, 2021 – Vivoryon Therapeutics N.V. […]
Vivoryon Therapeutics N.V. Reports H1 2021 Financial Results and Operational Progress
Strategic regional licensing partnership with Simcere Pharmaceutical Group to treat AD in Greater China US Phase 2 VIVA-MIND study for varoglutamstat in AD initiated as planned […]
Vivoryon Therapeutics N.V. to Publish its Financial Results for H1 2021 and Operational Progress
Halle (Saale) / Munich, Germany, September 14, 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development of […]
Vivoryon Therapeutics Provides Update on Financial Guidance
Halle (Saale) / Munich, Germany, June 29, 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical-stage biotechnology company focused on developing innovative small molecule-based […]
Vivoryon Therapeutics and Simcere Announce Strategic Regional Licensing Partnership to Develop and Commercialize N3pE Amyloid-targeting Medicines to Treat Alzheimer’s Disease in Greater China
Halle (Saale) / Munich, Germany and Nanjing, China, June 29, 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) a clinical-stage biotechnology company focused on developing […]
Ordinary General Meeting of Shareholders of Vivoryon Therapeutics N.V.
HALLE (SAALE) / MUNICH, GERMANY, June 28, 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) a clinical-stage biotechnology company focused on developing innovative small […]
Vivoryon Therapeutics Announces Financial Results for the First Quarter of 2021 and Provides Corporate Update
HALLE (SAALE) / MUNICH, GERMANY, June 25, 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) today announced financial results and provided a corporate update for […]
Vivoryon Therapeutics Reschedules Reporting of 1st Quarter 2021 and Provides Update for Annual General Meeting of Shareholders
HALLE (SAALE) / MUNICH, GERMANY, May 31, 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) announced today that the publication of the 1st quarter 2021 […]
Vivoryon Therapeutics Announces Notice of its Annual General Meeting of Shareholders to be Held on June 28, 2021
HALLE (SAALE) / MUNICH, GERMANY, May 17, 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) invites all shareholders to Vivoryon’s annual general meeting of shareholders to […]
Vivoryon Therapeutics N.V. Reports Full Year 2020 Financial Results
English conference call and webcast today, April 30th at 3:00 pm CEST (09:00 am EDT) a HALLE (SAALE) / MUNICH, GERMANY, April 30, 2021 – Vivoryon Therapeutics N.V. […]
Vivoryon Therapeutics N.V. Reschedules the Reporting of the Full Year 2020 Financial Results to April 30, 2021
HALLE (SAALE) / MUNICH, GERMANY, 14 April 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) announced today that the publication of the Full Year 2020 […]
Vivoryon Therapeutics to Host Virtual Event on Current Clinical Landscape in Alzheimer’s Disease Treatment Options with Leaders and Experts on April 15th, 2021
HALLE (SAALE) / MUNICH, GERMANY, 1 April 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) announced today that it will host a virtual event […]
Extraordinary General Meeting of Shareholders of Vivoryon Therapeutics N.V.
All proposed resolutions approved with large majority HALLE (SAALE) / MUNICH, GERMANY, 12 March 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) announced today […]
Vivoryon Therapeutics N.V. Announces Nominations to Reappoint Ulrich Dauer as CEO and to Appoint Florian Schmid as CFO
HALLE (SAALE) / MUNICH, GERMANY, 29 January 2021 – the Board of Directors (Board) of Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) announced today that […]
Vivoryon Therapeutics N.V. new ISIN code
HALLE (SAALE) / MUNICH, Germany, 06 January 2021 – in connection with the conversion into an N.V., a public company under the laws of the Netherlands (naamloze […]
Vivoryon Therapeutics N.V. new Home Member State
HALLE (SAALE) / MUNICH, Germany, 16 December 2020 – as a consequence of the conversion into an N.V., a public company under the laws of the Netherlands […]
Successful Relocation of Vivoryon Shares Package
HALLE (SAALE) / MUNICH, GERMANY, 14 December 2020 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; ISIN DE0007921835) has been informed by Hauck & Aufhäuser Privatbankiers AG […]
Vivoryon Therapeutics AG Announces Conversion into Vivoryon Therapeutics N.V.
HALLE (SAALE) / MUNICH, Germany, 30 November 2020 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY) announced today that it has completed its conversion into an N.V., a […]
Vivoryon Therapeutics Reports Third Quarter 2020
HALLE (SAALE) / MUNICH, Germany, 26 November 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY; ISIN DE0007921835) announced today its third quarter business update for the period […]
Vivoryon Therapeutics AG to Publish its Third Quarter 2020 Business Update on November 26, 2020
HALLE (SAALE) / MUNICH, Germany, 19 November 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835), a biotechnology company focused on developing first-in-class therapeutics targeting post-translational modifying […]
Ordinary General Meeting of Shareholders of Vivoryon Therapeutics AG
All proposed resolutions approved with large majority HALLE (SAALE) / MUNICH, Germany, 01 October 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) announced today […]
Vivoryon Therapeutics Announces Notice of its Ordinary General Meeting of Shareholders to be Held on September 30, 2020
HALLE (SAALE) / MUNICH, GERMANY, 3 September 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) invites all shareholders to Vivoryon Therapeutics´ ordinary general meeting of […]
Vivoryon Therapeutics AG plans conversion into Naamloze Vennootschap (N.V.) under Dutch law
Vivoryon Therapeutics intends the transfer of the statutory seat to Amsterdam, the Netherlands, leading to a conversion into a public company under the laws of the […]
Vivoryon Therapeutics AG Reports Financial Results for H1 2020 and Provides Corporate Update
Conference call and webcast in English at 3:00 pm CEST / 09:00 am EDT Vivoryon and Nordic Bioscience collaboration Meprin protease inhibitors development program HALLE (SAALE) / […]
Vivoryon Therapeutics AG to Publish its Half Year 2020 Results on August 27, 2020
HALLE (SAALE) / MUNICH, Germany, 20 August 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835), will publish its Half Year Results for 2020 on Thursday, August 27, […]
Vivoryon Receives IND Approval for Varoglutamstat‘s (PQ912) Phase 2 Study in Alzheimer’s Disease
HALLE (SAALE) / Munich, Germany, 04 August 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) today announced that the U.S. Food and Drug Administration (FDA) […]
Vivoryon Therapeutics Announces Enrollment of First Patient in VIVIAD, European Phase 2b Alzheimer’s Disease Study with Varoglutamstat (PQ912)
HALLE (SAALE) / Munich, Germany, 15 July 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) today announced that the first patient has been enrolled in […]
Vivoryon Therapeutics Provides Update on US and EU Alzheimer’s Clinical Trial Program with PQ912
Vivoryon and the Alzheimer’s Disease Cooperative Study (ADCS) have developed a new trial design for Phase 2a Alzheimer’s trial in the US; as a stage gate […]
Vivoryon Therapeutics AG Reports First Quarter 2020
HALLE (SAALE) / MUNICH, Germany, 14 May 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) announced today its first quarter business update for the period […]
Vivoryon Therapeutics AG Postpones Annual General Meeting
HALLE (SAALE) / Munich, Germany, 12 May 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) today announced the postponement of the Annual General Meeting which […]
Vivoryon Therapeutics AG to Publish its First Quarter 2020 Business Update on May 14, 2020
HALLE (SAALE) / Munich, Germany, 7 May 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835), which develops first-in-class drugs targeting post-translational modifying enzymes, will publish […]
Vivoryon Therapeutics Announces Outcome of Exclusive Option Deal with MorphoSys
MorphoSys will not execute the option deal to license Vivoryon’s small molecule QPCTL inhibitors for oncology Vivoryon will continue to evaluate QPCTL inhibitors in oncology […]
Vivoryon Therapeutics Starts Development Program for Meprin Protease Inhibitors with Intended Therapeutic Use in Fibrosis, Cancer and Alzheimer’s Disease
HALLE (SAALE) / MUNICH and LEIPZIG, Germany, 16 April 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) announced today that the Company has entered […]
CORRECTION: Vivoryon Therapeutics AG Reports Full Year 2019 Financial Results
This is a correction of the announcement from 07:00 am CET March 26, 2020. Reason for the correction: > As of December 31, 2019, the Loss […]
Vivoryon Therapeutics AG Reports Full Year 2019 Financial Results
Conference call and webcast (in English) at 3:00 pm CET (10:00 am EDT) HALLE (SAALE)/MUNICH, Germany, 26 March 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY; ISIN: DE007921835), today […]
Vivoryon Therapeutics AG to Publish its Full Year 2019 Results on March 26, 2020
HALLE (SAALE) / MUNICH, Germany, 19 March 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835), will publish its Full Year Results for 2019 on Thursday, […]
Vivoryon Therapeutics Announces Update on Phase 2b Alzheimer’s Clinical Trial, VIVIAD
Vivoryon has extended the trial protocol through the inclusion of exploratory parameters and plans to enroll patients in selected study sites in Denmark, Germany and the […]
Vivoryon Therapeutics to Attend Upcoming Investor Conferences
HALLE (SAALE)/MUNICH, Germany, 3 March 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835), announced today that its management will be presenting at and attending the […]
Vivoryon Therapeutics and Nordic Bioscience Enter Research and Development Collaboration
HALLE (SAALE), Germany and Herlev, Denmark, 14 January 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) and Nordic Bioscience, announced today an agreement to collaborate […]
Vivoryon Therapeutics to Attend 38th Annual J.P. Morgan Healthcare Conference in January 2020
HALLE (SAALE), Germany, 7 January 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835), announced today that the company is scheduled to attend the J.P. Morgan […]
Vivoryon Therapeutics is Included in AScX Index
HALLE (SAALE), Germany, 20 December 2019 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835), announced today that the company has been included in the AScX index as of […]
Vivoryon Therapeutics Reports Third Quarter 2019
HALLE (SAALE), Germany, 28 November 2019 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY; ISIN: DE0007921835), announced today its third quarter business update for the period ending September […]
Vivoryon Therapeutics attends CTAD 2019
HALLE (SAALE), Germany, 27 November 2019 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY; ISIN: DE0007921835), announced today that management of Vivoryon Therapeutics will attend the CTAD […]
Vivoryon Therapeutics AG to Publish Third Quarter 2019 Results on November 28, 2019
HALLE (SAALE), Germany, 21 November 2019 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY), will publish its third quarter financial results and a business update for the period […]
Vivoryon Therapeutics to Attend and Present at Investor Conferences in November 2019
HALLE (SAALE), Germany, 4 November 2019 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY), announced today that the company is scheduled to attend and present at upcoming conferences […]
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS RELEASE.
Vivoryon Therapeutics AG Successfully Completes a EUR 43 Million Capital Raise HALLE (SAALE), Germany, 24 October 2019 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN: DE0007921835, […]
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS RELEASE.
Vivoryon Therapeutics AG Launches Rights Offering to Fund its Phase 2b Clinical Development Program in Alzheimer’s Disease with Strong Commitments HALLE (SAALE), Germany, 08 October […]
Vivoryon Therapeutics Reports Financial Results for H1 2019 and Corporate Update
Conference call and webcast in English at 3:00 pm CEST / 09:00 am EST Successful private placement of EUR 8.2 million Strategic collaboration with MorphoSys announced in July […]
Vivoryon Therapeutics AG to Publish its Half Year 2019 Results on August 29, 2019
HALLE (SAALE), Germany, 22 August 2019 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY), will publish its Half Year Results for 2019 on Thursday, August 29, 2019. The […]
MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule Inhibitors of CD47-SIRP alpha Signaling in Immuno-Oncology
HALLE (SAALE) and PLANEGG/MUNICH Germany, 8 July 2019: Vivoryon Therapeutics AG (Euronext Amsterdam: VVY) and MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: […]
Vivoryon Therapeutics AG enters myeloid immune checkpoint drug discovery, and collaborates with the University of Kiel to select cancer therapy candidates from its QPCTL inhibitor portfolio
HALLE (SAALE), Germany, 27 June 2019 – Vivoryon Therapeutics AG, (Euronext Amsterdam: currently PBD, to be changed to VVY, ISIN: DE0007921835) announced today that they have […]
Vivoryon Therapeutics mandates goetzpartners as strategic business development advisor for expansion of its innovative QPCTL technology into immuno-oncology
HALLE (SAALE) and MUNICH, Germany, 18 June 2019 – Vivoryon Therapeutics AG, (Euronext Amsterdam: currently PBD, to be changed to VVY, ISIN: DE0007921835), a clinical stage precision […]
Probiodrug AG becomes Vivoryon Therapeutics AG
Healthy Aging – Pioneering Innovation HALLE (SAALE), Germany, 12 June 2019 – Probiodrug AG (Euronext Amsterdam: currently PBD, to be changed to VVY, ISIN: DE0007921835), focusing on […]
Ordinary General Meeting of Shareholders of Probiodrug AG
All proposed resolutions approved with large majority HALLE (SAALE), Germany, 29 May 2019 – Probiodrug AG (Euronext Amsterdam: PBD), announces that its shareholders approved all resolutions […]
Probiodrug to attend International Conferences in June 2019
HALLE (SAALE), Germany, 22 May 2019 – Probiodrug AG (“Probiodrug”, Euronext: PBD), announces that the company is scheduled to attend the following conferences: (1) 2019 BIO […]
Probiodrug Reports First Quarter 2019 Business Update
HALLE (SAALE), Germany, 16 May 2019 – Probiodrug AG (Euronext Amsterdam: PBD), announced today its first quarter business update for the period ending March 31, 2019. The […]
Probiodrug AG to Publish its First Quarter 2019 Business Update on May 16, 2019
HALLE (SAALE), Germany, 9 May 2019 – Probiodrug AG (Euronext Amsterdam: PBD, ISIN: DE0007921835), is focusing on the discovery and development of drugs acting on enzymes which […]
Probiodrug AG to hold its Ordinary General Meeting of Shareholders on 29 May 2019
HALLE (SAALE), Germany, 18 April 2019 – Probiodrug AG (Euronext Amsterdam: PBD; ISIN: DE0007921835), invites all shareholders to Probiodrugs ordinary general meeting of shareholders to be […]
Probiodrug raises EUR 8.2 million in successful private placement of new shares
Consortium of strategic investors led by Dr. Claus Christiansen founder and chairman of the board of Nordic Bioscience, Denmark, invests EUR 6.2 million Proceeds used to […]
Probiodrug raises EUR 8.2 million from investors in successful private placement of new shares
NOT FOR PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA Probiodrug raises EUR 8.2 million from investors in successful private […]
Probiodrug AG has mandated ODDO SEYDLER BANK AG as Designated Sponsor
The shares are trading on XETRA, the electronic trading platform of Deutsche Börse. HALLE (SAALE), Germany, 04 APRIL 2019 – Shares in Probiodrug AG, (Euronext […]
Probiodrug reports full year 2018 financial results
Conference call and webcast (in English) at 3:00 pm CET (10:00 am EDT) NIH grant of 15million USD received PQ912 Phase 2b core program prepared HALLE (SAALE), […]
Probiodrug AG to Publish its Full Year 2018 Results on March 28, 2019
HALLE (SAALE), Germany, 21 March 2019 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish […]
Probiodrug and Alzheimer’s Disease Cooperative Study (ADCS) Receive 15 Million USD National Institutes of Health (NIH) Grant for U.S. Phase 2b Core Program for PQ912
Study to Evaluate Safety and Efficacy of Drug Seeking to Treat Those with Mild Cognitive Impairment or Mild Dementia HALLE (SAALE), Germany and San Diego, […]
Probiodrug to attend BIO Europe Spring in March 2019
HALLE (SAALE), Germany, 12 March 2019 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]
Probiodrug to attend International Conferences in February 2019
HALLE (SAALE), Germany, 5 February 2019 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]
Probiodrug to attend at J.P. Morgan Healthcare Conference in January 2019
HALLE (SAALE), Germany, 18 December 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]
Probiodrug to present at Antibody Engineering & Therapeutics in December 2018
HALLE (SAALE), Germany, 04 December 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]
Probiodrug AG Reports Third Quarter 2018 Business Update
HALLE (SAALE), Germany, 29 November 2018 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announces […]
Probiodrug AG to Publish its Third Quarter 2018 Business Update on November 29, 2018
Probiodrug AG to Publish its Third Quarter 2018 Business Update on November 29, 2018 HALLE (SAALE), Germany, 22 November 2018 – Probiodrug AG (Euronext […]
Probiodrug to Attend and Present at International Conferences in November 2018
HALLE (SAALE), Germany, 29 October, 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]
Probiodrug publishes SAPHIR data in peer reviewed journal
SAPHIR trial data published in Alzheimer’s Research & Therapy HALLE (SAALE), Germany, 16 October 2018 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company […]
Probiodrug AG: Loss announcement according to §92 paragraph 1 of the German Stock Corporation Act
HALLE (SAALE), Germany, 15 October 2018 – The management board of Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to […]
Probiodrug to attend International Conferences in October 2018
HALLE (SAALE), Germany, 09 October, 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]
Probiodrug Reports Management Changes
HALLE (SAALE), Germany, October 5th, 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announced today […]
Probiodrug Appoints Dr. Michael Schaeffer as Executive Vice President of Business and Strategy
HALLE (SAALE), Germany, 04 September, 2018: Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today […]
Probiodrug Reports Financial Results for H1 2018 and Corporate Update
HALLE (SAALE), Germany, 30 August 2018 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announces […]
Probiodrug AG to Publish First Half 2018 Results on August 30, 2018
HALLE (SAALE), Germany, 23 August 2018 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish its […]
Ordinary General Meeting of Shareholders of Probiodrug AG
All proposed resolutions approved with large majority HALLE (SAALE), Germany, 22 June 2018 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel […]
Probiodrug to attend and present at the BIO International Convention in June 2018
HALLE (SAALE), Germany, 29 May 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]
Probiodrug updated Privacy Policy
HALLE (SAALE), Germany, 25 May 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces today […]
Probiodrug AG reports First Quarter 2018 Business Update
HALLE (SAALE), Germany, 15 May 2018 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today […]
Probiodrug AG to hold its Ordinary General Meeting of Shareholders on 21 June 2018
HALLE (SAALE), Germany, 09 May 2018 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), has […]
Probiodrug positioning its pGlu-Abeta Antibody in the field of Abeta antibodies
Probiodrug co-authored a review paper entitled “Passive Aβ Immunotherapy: Current Achievements and Future Perspectives “ HALLE (SAALE), Germany, 08 May 2018 Probiodrug AG (Euronext […]
Probiodrug AG to Publish its First Quarter 2018 Business Update on 15 May 2018
HALLE (SAALE), Germany, 8 May 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will […]
Probiodrug to attend and present at International Conferences in May 2018
HALLE (SAALE), Germany, 04 May 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]
Probiodrug Appoints Dr. Ulrich Dauer as Chief Executive Officer
Dr. Ulrich Dauer to team up with Chief Development Officer, Dr. Inge Lues, effective May 1, 2018; Dr. Konrad Glund and Dr. Hendrik Liebers to continue […]
Probiodrug to attend and present at International Conferences in April 2018
HALLE (SAALE), Germany, 10 April 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]
Probiodrug reports full year 2017 financial results
PQ912 delivers positive pharmacodynamic and efficacy results in a Phase 2a study in early stage AD patients – data presented at CTAD, Boston, November 2017 PQ912 Phase […]
Probiodrug AG to Publish its Full Year 2017 Results on 3 April 2018
HALLE (SAALE), Germany, 27 March 2018 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish […]
Probiodrug to present at 255th ACS National Meeting & Exposition
The Inhibition of Glutaminyl Cyclase as a New Concept for the Treatment of Alzheimer’s Disease: PQ912, the First-In-Class QC-Inhibitor in Clinical Development for AD HALLE […]
Probiodrug to attend and present at International Conferences in March 2018
HALLE (SAALE), Germany, 27 February 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]
Probiodrug to attend and present at upcoming international conferences
HALLE (SAALE), Germany, 23 January 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]
Probiodrug to attend and present at international conferences in January 2018
HALLE (SAALE), Germany, 14 December 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]
Probiodrug and Crossbeta Biosciences extend their strategic partnership in the field of Alzheimer’s disease biomarkers
HALLE (SAALE), Germany, UTRECHT, The Netherlands, 5 December 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease […]
Probiodrug reports Third Quarter 2017 Business Update
HALLE (SAALE), Germany, 30 November 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announces […]
Probiodrug AG to Publish its Third Quarter 2017 Business Update on 30 November 2017
HALLE (SAALE), Germany, 23 November 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish its […]
Probiodrug to Present Data from its Phase 2a SAPHIR Study at International Alzheimer’s Disease Conference
Prof. Philipp Scheltens, Principal Investigator of the study, to present at Clinical Trials on Alzheimer’s Disease (CTAD) 2017 in Boston Management will host a conference […]
Probiodrug to present at Life Sciences Conferences in November
HALLE (SAALE), Germany, 24 October 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]
Probiodrug initiates Phase 2b core program of PQ912 and details further strategy
Company moves seamlessly from finalization of the SAPHIR Phase 2a to next clinical stage Probiodrug takes a double-pronged strategy – starts operational preparation of clinical studies […]
Probiodrug to present at Life Sciences Conferences in October 2017
HALLE (SAALE), Germany, 28 September 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]
Probiodrug reports financial results for H1 2017 and corporate update
PQ912 delivers positive pharmacodynamic and efficacy results in a Phase-2a study in early stage AD patients Successful settlement of longpending tax issue PQ912 demonstrates efficacy in […]
Probiodrug to present and attend at International Conferences in September 2017
HALLE (SAALE), Germany, 30 August 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]
Unique binding mode of PBD-C06 to pGlu-Abeta peptides identified
Probiodrug publishes mechanism of target binding for its lead anti-pGlu-Abeta monoclonal antibody PBD-C06 HALLE (SAALE), Germany, 29 August 2017 – Probiodrug AG (Euronext Amsterdam: PBD), […]
Probiodrug AG to Publish First Half 2017 Results on 31 August 2017
HALLE (SAALE), Germany, 24 August 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish its results […]
Ordinary General Meeting of Shareholders of Probiodrug AG
All proposed resolutions approved with large majority HALLE (SAALE), Germany, 14 June 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions […]
Probiodrug announces encouraging results of the Phase 2a SAPHIR Study
HALLE (SAALE), Germany, 11 June 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announced […]
Probiodrug to present and attend at International Conferences in June 2017
HALLE (SAALE), Germany, 30 May 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]
Probiodrug AG Announces Acceptance of PQ912 Pharmacology Paper by Peer Reviewed Journal
HALLE (SAALE), Germany, 16 May 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announces […]
Probiodrug AG reports First Quarter 2017 Business Update
HALLE (SAALE), Germany, 12 May 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announces […]
Probiodrug AG to Publish its First Quarter 2017 Business Update on 12 May 2017
HALLE (SAALE), Germany, 5 May 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish its […]
Probiodrug AG to hold its Ordinary General Meeting of Shareholders on 13 June 2017
HALLE (SAALE), Germany, 02 May 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), has the honour […]
Probiodrug to attend an present at International Conferences in May 2017
HALLE (SAALE), Germany, 25 April 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]
Probiodrug to present at Huntington’s Disease Therapeutics Conference
The Glutaminyl Cyclase (QC) inhibitor PQ912 demonstrates beneficial effects in a preclinical Huntington´s disease model HALLE (SAALE), Germany, 10 April 2017 – Probiodrug AG (Euronext […]
Last Patient Last Visit (LPLV) reached in the SAPHIR Study
Last Patient Last Visit (LPLV) reached in the SAPHIR Study, a Phase 2 trial with the Glutaminyl Cyclase (QC) inhibitor PQ912 in early Alzheimer’s Disease (AD) […]
Probiodrug to attend International Conferences in April 2017
HALLE (SAALE), Germany, 03 April 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]
Probiodrug reports full year 2016 financial results
SAPHIR, the Phase 2a study of PQ912 as a novel treatment for Alzheimer’s disease fully enrolled Favourable results of chronic toxicology studies with PQ912 announced Promising […]
Probiodrug to present at Alzheimer’s and Parkinson’s Diseases Congress
New results of a double pronged-approach to target the neurotoxic amyloid beta species pGlu-Abeta, and an evaluation of new biomarkers in cerebrospinal fluid (CSF) from AD […]
Probiodrug AG to Publish its Full Year 2016 Results on 30 March 2017
HALLE (SAALE), Germany, 23 March 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish its Full […]
Probiodrug to attend and present at International Conferences in March 2017
HALLE (SAALE), Germany, 06 March 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]